Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 3
1967 2
1968 5
1969 5
1970 4
1973 4
1974 2
1975 4
1976 3
1977 2
1978 1
1979 2
1982 1
1983 3
1984 4
1985 4
1986 2
1987 4
1988 5
1989 6
1990 16
1991 5
1992 12
1993 6
1994 16
1995 14
1996 23
1997 16
1998 19
1999 12
2000 13
2001 11
2002 16
2003 8
2004 13
2005 9
2006 9
2007 6
2008 7
2009 7
2010 12
2011 14
2012 7
2013 5
2014 11
2015 5
2016 8
2017 5
2018 4
2019 3
2020 5
2021 3
2022 3
2023 2
2024 9
2025 2
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

381 results

Results by year

Filters applied: . Clear all
Page 1
Megestrol acetate.
Canetta R, Florentine S, Hunter H, Lenaz L. Canetta R, et al. Cancer Treat Rev. 1983 Sep;10(3):141-57. doi: 10.1016/0305-7372(83)90029-4. Cancer Treat Rev. 1983. PMID: 6352021 Review. No abstract available.
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.
Mirza MR, Bjørge L, Marmé F, Christensen RD, Gil-Martin M, Auranen A, Ataseven B, Rubio MJ, Salutari V, Luczak AA, Runnebaum IB, Redondo A, Lindemann K, Trillsch F, Ginesta MPB, Roed H, Kurtz JE, Petersson KS, Nyvang GB, Sehouli J. Mirza MR, et al. Gynecol Oncol. 2025 Jan;192:128-136. doi: 10.1016/j.ygyno.2024.12.003. Epub 2024 Dec 9. Gynecol Oncol. 2025. PMID: 39657575 Free article. Clinical Trial.
Patients were randomized in a 1:1 ratio, stratified by number of prior chemotherapy lines, measurable versus evaluable non-measurable disease, and prior medroxyprogesterone/megestrol acetate treatment, to receive oral letrozole 2.5 mg on days 1-28 plus either oral palbocic …
Patients were randomized in a 1:1 ratio, stratified by number of prior chemotherapy lines, measurable versus evaluable non-measurable diseas …
RETRACTED: The use of oral nomegestrol acetate/estradiol in rapid and random start preparation of endometrium before office hysteroscopic polypectomies: A multicenter, prospective, randomized controlled trial.
Etrusco A, Agrifoglio V, Chiantera V, D'Amato A, Russo G, Golia D'Augè T, Giannini A, Riemma G, Pecorino B, Ferrari F, Laganà AS, Monti M. Etrusco A, et al. Eur J Obstet Gynecol Reprod Biol. 2024 Aug;299:213-218. doi: 10.1016/j.ejogrb.2024.06.019. Epub 2024 Jun 10. Eur J Obstet Gynecol Reprod Biol. 2024. Retraction in: Eur J Obstet Gynecol Reprod Biol. 2026 May;321:115081. doi: 10.1016/j.ejogrb.2026.115081. PMID: 38897097 Free article. Retracted. Clinical Trial.
Metastatic breast cancer.
Rubens RD. Rubens RD. Curr Opin Oncol. 1995 Nov;7(6):523-6. doi: 10.1097/00001622-199511000-00008. Curr Opin Oncol. 1995. PMID: 8547400 Review.
The cyclical sequential use of tamoxifen with megestrol acetate has not increased the response over tamoxifen alone. Aromatase inhibitors are an expanding field; formestane and vorozole are effective agents, and letrozole shows promise. ...
The cyclical sequential use of tamoxifen with megestrol acetate has not increased the response over tamoxifen alone. Aromatase inhibi …
[Megestrol acetate in various doses in the treatment of metastatic breast carcinoma--clinical and endocrinologic studies].
Wander HE, Blossey HC, Nagel GA, Emrich D. Wander HE, et al. Klin Wochenschr. 1985 Apr 1;63(7):312-8. doi: 10.1007/BF01731974. Klin Wochenschr. 1985. PMID: 2987601 Clinical Trial. German.
Both medroxyprogesterone acetate (MPA) and megestrol acetate (MA) are effective in the treatment of metastatic breast cancer. Although the dose-dependent mode of actions of MPA have been extensively clarified, there is still some uncertainty regarding the mode of actions a …
Both medroxyprogesterone acetate (MPA) and megestrol acetate (MA) are effective in the treatment of metastatic breast cancer. Althoug …
Palonosetron Plus Megestrol Acetate Versus Palonosetron Plus Dexamethasone in Preventing Moderately Emetogenic Chemotherapy-induced Nausea and Vomiting: A Randomized, Multicenter, Crossover Trial.
Li Q, Luo Y, Zhao Y, Gou H, Min S, Yang B, Yi C. Li Q, et al. J Pain Symptom Manage. 2025 Dec;70(6):557-568.e1. doi: 10.1016/j.jpainsymman.2025.07.034. Epub 2025 Aug 26. J Pain Symptom Manage. 2025. PMID: 40876663 Clinical Trial.
BACKGROUNDS: Evidence shows that megestrol acetate (MA) is a potential antiemetic for preventing chemotherapy-induced nausea and vomiting (CINV). ...
BACKGROUNDS: Evidence shows that megestrol acetate (MA) is a potential antiemetic for preventing chemotherapy-induced nausea and vomi …
Mirtazapine versus megestrol acetate in treatment of anorexia-cachexia in advanced cancer patients: a randomized, double-blind trial.
Chowdhury IH, Rahman MS, Chowdhury MNK, Afroze YJ, Tabassum M, Marnush M, Zerin N. Chowdhury IH, et al. Jpn J Clin Oncol. 2024 May 7;54(5):530-536. doi: 10.1093/jjco/hyae009. Jpn J Clin Oncol. 2024. PMID: 38323684 Free article. Clinical Trial.
The control arm received the standard chemotherapy medication plus one tablet of megestrol acetate 160 mg daily orally for 8 weeks starting from the day of an initial assessment. ...However, the improvement after 4 to 8 weeks was not statistically significant when it was c …
The control arm received the standard chemotherapy medication plus one tablet of megestrol acetate 160 mg daily orally for 8 weeks st …
Megestrol melanoma study.
Nathanson L, Garrison M. Nathanson L, et al. World J Surg. 1995 May-Jun;19(3):337-42. doi: 10.1007/BF00299153. World J Surg. 1995. PMID: 7638983 Clinical Trial.
The progestogen megestrol acetate (160 mg/day PO continuously starting 2 days before chemotherapy) plus chemotherapy with dacarbazine (220 mg/m2/day IV for 3 days), cisplatin (25-30 mg/m2/day IV for 3 days) every 3 weeks, and carmustine (150 mg/m2 IV single dose every 6 we …
The progestogen megestrol acetate (160 mg/day PO continuously starting 2 days before chemotherapy) plus chemotherapy with dacarbazine …
Comparing the Administration of Letrozole and Megestrol Acetate in the Treatment of Women with Simple Endometrial Hyperplasia without Atypia: A Randomized Clinical Trial.
Moradan S, Nikkhah N, Mirmohammadkhanai M. Moradan S, et al. Adv Ther. 2017 May;34(5):1211-1220. doi: 10.1007/s12325-017-0509-8. Epub 2017 Mar 28. Adv Ther. 2017. PMID: 28353144 Clinical Trial.
The first group received 40-mg doses of Megestrol acetate for 2 weeks per month for a total period of 2 months. The second group received 2.5-mg daily doses of Letrozole for a total period of 2 months. ...CONCLUSION: Letrozole and Megestrol acetate seem to have simi …
The first group received 40-mg doses of Megestrol acetate for 2 weeks per month for a total period of 2 months. The second group rece …
Cyclic sequential endocrine therapy for advanced breast cancer using a combination of tamoxifen and megestrol acetate.
Crawford DJ, George WD, Smith DC, Stewart M, Paul J, Leake RE. Crawford DJ, et al. Oncology. 1994 Oct;51 Suppl 1:13-8. doi: 10.1159/000227410. Oncology. 1994. PMID: 7970503 Clinical Trial.
A cyclical, sequential combination of tamoxifen and megestrol acetate (group B) was compared with conventional therapy (tamoxifen alone, group A) in 261 breast cancer patients. ...
A cyclical, sequential combination of tamoxifen and megestrol acetate (group B) was compared with conventional therapy (tamoxifen alo …
381 results